公开(公告)号：US5602140A

公开(公告)日：1997-02-11

申请号：US410838

申请日：1995-03-27

申请人： Yoshiaki Isobe ,  Nobuyoshi Chiba ,  Yuso Goto ,  Hideharu Sato

发明人： Yoshiaki Isobe ,  Nobuyoshi Chiba ,  Yuso Goto ,  Hideharu Sato

IPC分类号： C07D233/90 ,  C07D473/30 ,  A61K31/52

CPC分类号： C07D473/30

摘要： Purine derivatives shown by general formula [I] or pharmacologically acceptable salts thereof. Suppressants for inflammatory diseases containing an effective ingredient of said purine derivative. ##STR1## (wherein, R represents one group selected from the groups composed of H atom, a straight chain alkyl group having 1-10 carbon atoms, a branched chain alkyl group having 3-10 carbon atoms, an alkyl group having 1-10 carbon atoms substituted with one carboxyl group, 4-carboxybenzyl group and phenethyl group).Above mentioned purine derivatives prevent the tissue damages due to mediators such as active oxygen and TXA.sub.2 in the initial stage of inflammation, and prevent the subsequent aggravation of inflammatory responses due to the adhesion of activated leukocytes to the cells in the lesion, and exhibit efficacy as anti-inflammatory drugs in all stages of inflammatory diseases caused by leukocytes.

摘要翻译： 由通式[I]表示的嘌呤衍生物或其药理学上可接受的盐。 含有所述嘌呤衍生物的有效成分的炎性疾病抑制剂。 （I）（I）（其中，R表示选自由H原子，具有1-10个碳原子的直链烷基，具有3-10个碳原子的支链烷基组成的基团中的一个基团， 1-10个碳原子被一个羧基取代，4-羧基苄基和苯乙基）。 上述嘌呤衍生物可防止炎症初期由于诸如活性氧和TXA2等介质而导致的组织损伤，并且防止由于活化的白细胞粘附于病变中的细胞而导致的炎性反应的随后恶化， 抗炎药物在白细胞引起的炎症性疾病的各个阶段。

公开(公告)号：US08412940B2

公开(公告)日：2013-04-02

申请号：US13057468

申请日：2009-08-21

申请人： Kenta Takahashi ,  Shinji Hirata ,  Yoshiaki Isobe

发明人： Kenta Takahashi ,  Shinji Hirata ,  Yoshiaki Isobe

IPC分类号： H04L29/06

CPC分类号： H04L63/0861 ,  G06F21/32 ,  G06F21/83 ,  G06F2221/2153 ,  G06K2009/00953 ,  G07C9/00158 ,  G07C9/00166 ,  G07C2209/12 ,  H04L9/3231 ,  H04L2209/043

摘要： At registration time, feature data array for registration is generated from biometric information, and position correction template and comparison template. At authentication time, feature data array for authentication is generated from biometric information acquired by the client, and converted feature data for position correction obtained by converting the feature data array for authentication is transmitted to the server. The server detects position correction amount of the feature data array for authentication relative to the feature data array for registration using the position correction template and the converted feature data, and transmits the position correction amount to client. Client corrects the feature data array for authentication and transmits the converted feature data array for comparison to the server. Server calculates a distance between the comparison template and the converted feature data array for comparison and determines success or failure of the authentication on the basis of the distance.

摘要翻译： 在注册时，从生物特征信息和位置校正模板和比较模板生成用于注册的特征数据阵列。 在验证时，由客户端获取的生物特征信息生成用于认证的特征数据阵列，并将用于认证的特征数据阵列转换获得的用于位置校正的转换特征数据发送到服务器。 服务器使用位置校正模板和转换的特征数据来检测用于认证的特征数据阵列的位置校正量，并且将位置校正量发送给客户端。 客户端更正特征数据阵列进行认证，并将转换的特征数据数组发送到服务器进行比较。 服务器计算比较模板和转换的特征数据数组之间的距离进行比较，并根据距离确定认证的成功或失败。

公开(公告)号：US20110306610A1

公开(公告)日：2011-12-15

申请号：US13187260

申请日：2011-07-20

申请人： Ayumu KURIMOTO ,  Kazuki Hashimoto ,  Yoshiaki Isobe ,  Stephen Brough ,  Ian Millichip ,  Hiroki Wada ,  Roger Bonnert ,  Thomas Mcinally

发明人： Ayumu KURIMOTO ,  Kazuki Hashimoto ,  Yoshiaki Isobe ,  Stephen Brough ,  Ian Millichip ,  Hiroki Wada ,  Roger Bonnert ,  Thomas Mcinally

IPC分类号： A61K31/522 ,  C07D413/14 ,  A61P37/08 ,  A61P37/00 ,  A61P31/12 ,  A61P35/00 ,  C07D473/18 ,  A61K31/5377

CPC分类号： C07D473/18 ,  A61K31/522 ,  A61K31/5377

摘要： The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.

摘要翻译： 本发明提供具有免疫调节活性的8-氧代腺嘌呤化合物，例如干扰素诱导活性，可用作抗病毒剂和抗变应性剂，其由下式（1）表示：[其中环A表示6-10元 芳香族碳环等，R表示卤素原子，烷基等，n表示0-2的整数，Z1表示亚烷基，X2表示氧原子，硫原子，SO2，NR5，CO，CONR5，NR5CO 等等，Y1，Y2和Y3独立地表示单键或亚烷基，X1表示氧原子，硫原子，NR4（R4是氢原子或烷基）或单键，R2表示取代或未取代的烷基 基团，R 1表示氢原子，羟基，烷氧基，烷氧基羰基或卤代烷基]或其​​药学上可接受的盐。

公开(公告)号：US20100298364A1

公开(公告)日：2010-11-25

申请号：US12784226

申请日：2010-05-20

申请人： Nicholas James BENNETT ,  Thomas McInally ,  Austen Pimm ,  Stephen Thom ,  Yoshiaki Isobe

发明人： Nicholas James BENNETT ,  Thomas McInally ,  Austen Pimm ,  Stephen Thom ,  Yoshiaki Isobe

IPC分类号： A61K31/505 ,  C07D239/48 ,  A61P11/06 ,  A61P35/00 ,  A61P31/18 ,  A61P31/20 ,  A61P31/04 ,  A61P31/14 ,  A61P17/00

CPC分类号： C07D239/49 ,  C07D275/06

摘要： The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy.

摘要翻译： 本发明提供2-（4 - （（2-氨基-4-甲基-6-（戊基氨基）嘧啶-5-基）甲基）苯基）乙酸4-（二甲基氨基）丁酯的盐，含有它们的药物组合物及其用途 在治疗。

公开(公告)号：US06376501B1

公开(公告)日：2002-04-23

申请号：US09582176

申请日：2000-06-21

申请人： Yoshiaki Isobe ,  Haruhisa Ogita ,  Masanori Tobe ,  Haruo Takaku ,  Hiroyuki Matsui ,  Hideyuki Tomizawa

发明人： Yoshiaki Isobe ,  Haruhisa Ogita ,  Masanori Tobe ,  Haruo Takaku ,  Hiroyuki Matsui ,  Hideyuki Tomizawa

IPC分类号： A61K3152

CPC分类号： A61K31/522 ,  A61K31/52 ,  C07D473/00 ,  C07D473/34

摘要： The present invention relates to a type 2 helper T cell-selective immune response inhibitor, an immune response regulator and an anti-allergic agent, individually comprising, as an active ingredient, a purine derivative represented by General Formula (I): wherein R2 is hydrogen or a hydrocarbon group in which —CH2— not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C—H not directly bound to the purine skeleton may be substituted by N, C-halogen or C—CN; R6 is hydroxyl, amino or amino which is mono- or di-substituted by a hydrocarbon group(s); R8 is hydroxyl, mercapto, acyloxy or hydrocarbon group-substituting oxycarbonyloxy; and R9 is a hydrocarbon group in which —CH2— not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C—H not directly bound to the purine skeleton may be substituted by N, C-halogen or C—CN; or its tautomer or a salt of the purine derivative or the tautomer.

摘要翻译： 本发明涉及一种2型辅助性T细胞选择性免疫应答抑制剂，免疫应答调节剂和抗过敏剂，其各自包含作为活性成分的由通式（I）表示的嘌呤衍生物：其中R 2为氢 或其中不直接结合嘌呤骨架的-CH 2可以被CO，SO 2，O或S取代的烃基，并且不直接键合到嘌呤骨架上的CH可以被N，C-卤素或C-CN R6是羟基，被一个或多个烃基单取代或二取代的氨基或氨基; R8是羟基，巯基，酰氧基或烃基取代的氧羰基氧基; 并且R 9是其中不直接结合嘌呤骨架的-CH 2可以被CO，SO 2，O或S取代的烃基，并且不直接键合到嘌呤骨架上的CH可以被N，C-卤素或C- CN;或其互变异构体或嘌呤衍生物或互变异构体的盐。

公开(公告)号：US06310070B1

公开(公告)日：2001-10-30

申请号：US09462861

申请日：2000-04-28

申请人： Akihisa Yokoyama ,  Sumitsugu Kisanuki ,  Yoshikazu Matsuda ,  Junko Matsui ,  Yoshiaki Isobe

发明人： Akihisa Yokoyama ,  Sumitsugu Kisanuki ,  Yoshikazu Matsuda ,  Junko Matsui ,  Yoshiaki Isobe

IPC分类号： C07D47330

CPC分类号： C07D473/30

摘要： A novel purine derivative exhibiting an effect to control inflammatory symptoms characteristic to nephritis and a medicine comprising this compound as an effective ingredient are provided. The compound is represented by the following general formula (I), wherein R1 is a hydrocarbon group having 17 or less carbon atoms and R2 is a hydrocarbon group having 16 or less carbon atoms, wherein one or more CH2 g roups in the hydrocarbon group which 7013 do not directly bind with the carbon atom at 2 or 7 position of the purine ring replaced are by carbonyl groups, sulfonyl groups, O, or S and/or one or more CH groups in the hydrocarbon group which do not directly bind with the carbon atom at 2 or 7 position of the purine ring are replaced by N, C-halogen, or C—C≡N, or a pharmaceutically acceptable salt thereof.

摘要翻译： 本发明提供了具有控制肾炎特征性炎症症状的效果的新型嘌呤衍生物和含有该化合物作为有效成分的药物。 该化合物由以下通式（I）表示，其中R 1是具有17个或更少碳原子的烃基，R 2是具有16个或更少碳原子的烃基，其中一个或多个在烃基中的CH 2 7013不与嘌呤环的2或7位的碳原子直接结合，所取代的碳原子是羰基，磺酰基，O或S和/或烃基中一个或多个不与直接键合的CH基团 嘌呤环2或7位的碳原子被N，C-卤素或CC = N取代，或其药学上可接受的盐。

公开(公告)号：US5821247A

公开(公告)日：1998-10-13

申请号：US933208

申请日：1997-09-16

申请人： Yoshiaki Isobe ,  Yuso Goto ,  Masanori Tobe ,  Osamu Takahashi

发明人： Yoshiaki Isobe ,  Yuso Goto ,  Masanori Tobe ,  Osamu Takahashi

IPC分类号： C07D239/54 ,  C07D239/545 ,  C07D405/12 ,  A61K31/51

CPC分类号： C07D239/545 ,  C07D405/12

摘要： Disclosed is a hydroquinone derivative or a pharmaceutically acceptable salt thereof, the hydroquinone derivative being represented by formula (I): ##STR1## wherein R.sup.1 is a phenyl group which is unsubstituted or substituted with a substituent or substituents each independently selected from the group consisting of a halogen atom, a C1-4 alkyl group and a C1-4 alkoxy group; R.sup.2 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.3 and R.sup.4 is independently a hydrogen atom or a C1-4 alkyl group; R.sup.5 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.6, R.sup.7 and R.sup.8 is independently a hydrogen atom or a C1-4 alkyl group; P is a hydroxyl group; Q is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group; P may form together with Q an ether bond; R is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group, provided that when one of said Q and said R is an oxo group, the other is also an oxo group; X is a single bond, an --NR.sup.10 --group or a --CH.sub.2 --NR.sup.10 --group in which R.sup.10 is a hydrogen atom or a C1-4 alkyl group; Y is a methylene group or a carbonyl group; and dotted bonds in a six membered ring represent that said six membered ring has the maximum number of double bonds.

摘要翻译： 公开了氢醌衍生物或其药学上可接受的盐，所述对苯二酚衍生物由式（I）表示：未取代的或被各自独立地选自卤素原子，C 1-4烷基的取代基或取代基取代 和C 1-4烷氧基; R2是氢原子或C1-4烷基; R 3和R 4各自独立地为氢原子或C 1-4烷基; R5是氢原子或C1-4烷基; R6，R7和R8各自独立地为氢原子或C1-4烷基; P是羟基; Q是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基; P可与Q形成醚键; R是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基，条件是当所述Q和所述R中的一个是氧代基时，另一个也是氧代基; X是单键，-NR 10 - 基或-CH 2 -NR 10 - 基，其中R 10是氢原子或C 1-4烷基; Y是亚甲基或羰基; 六元环中的点状键表示所述六元环具有最大数量的双键。

公开(公告)号：US08969362B2

公开(公告)日：2015-03-03

申请号：US14058064

申请日：2013-10-21

申请人： Ayumu Kurimoto ,  Kazuki Hashimoto ,  Yoshiaki Isobe ,  Stephen Brough ,  Ian Millichip ,  Hiroki Wada ,  Roger Bonnert ,  Thomas Mcinally

发明人： Ayumu Kurimoto ,  Kazuki Hashimoto ,  Yoshiaki Isobe ,  Stephen Brough ,  Ian Millichip ,  Hiroki Wada ,  Roger Bonnert ,  Thomas Mcinally

IPC分类号： A61K31/522 ,  C07D473/18 ,  A61K31/5377

CPC分类号： C07D473/18 ,  A61K31/522 ,  A61K31/5377

摘要： The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.

摘要翻译： 本发明提供具有免疫调节活性的8-氧代腺嘌呤化合物，例如干扰素诱导活性，可用作抗病毒剂和抗变应性剂，其由下式（1）表示：[其中环A表示6-10元 芳香族碳环等，R表示卤素原子，烷基等，n表示0-2的整数，Z1表示亚烷基，X2表示氧原子，硫原子，SO2，NR5，CO，CONR5，NR5CO 等等，Y1，Y2和Y3独立地表示单键或亚烷基，X1表示氧原子，硫原子，NR4（R4是氢原子或烷基）或单键，R2表示取代或未取代的烷基 基团，R 1表示氢原子，羟基，烷氧基，烷氧基羰基或卤代烷基]或其​​药学上可接受的盐。

公开(公告)号：US20130179957A1

公开(公告)日：2013-07-11

申请号：US13805628

申请日：2011-05-16

申请人： Osamu Takata ,  Yosuke Kaga ,  Yoshiaki Isobe ,  Masahiro Mimura ,  Nobuo Takahashi

发明人： Osamu Takata ,  Yosuke Kaga ,  Yoshiaki Isobe ,  Masahiro Mimura ,  Nobuo Takahashi

IPC分类号： H04L29/06

CPC分类号： H04L63/0861 ,  G06F21/32 ,  G06Q50/26 ,  G06Q50/265 ,  G07C9/00103 ,  G07C9/00158 ,  H04L9/3231

摘要： The present invention shortens the time required for watch list verification, and shortens the time required generally for the personal identification processing which includes watch list verification. In a personal identification system, a biometric information watch list comparison function (31) performs a first comparison of first biometric information in a traveler information DB (53), and biometric information on a biometric information watch list (52). Thereafter, a simplified alien immigration examination comparison function (41) performs a second comparison of the first biometric information in the traveler information DB (53), and second biometric information acquired by a biometric information acquisition function (62). As a result of the comparison, in the case where the difference between the time of the first comparison and the current time is within a previously defined time period, a terminal displays a first comparison result, and a second comparison result.

摘要翻译： 本发明缩短了观看列表验证所需的时间，缩短了包括观看列表验证在内的个人识别处理所需的时间。 在个人识别系统中，生物体信息观察列表比较功能（31）对旅行者信息DB（53）中的第一生物体信息和生物体信息监视列表（52）的生物体信息进行第一比较。 此后，简化的外来移民检查比较功能（41）对旅行者信息DB（53）中的第一生物特征信息和通过生物体信息获取功能（62）获取的第二生物信息进行第二比较。 作为比较的结果，在第一比较的时间与当前时间之间的差异在预定的时间段内的情况下，终端显示第一比较结果和第二比较结果。

公开(公告)号：US20130088327A1

公开(公告)日：2013-04-11

申请号：US13587212

申请日：2012-08-16

申请人： Kenta Takahashi ,  Yoshiaki Isobe

发明人： Kenta Takahashi ,  Yoshiaki Isobe

IPC分类号： G05B19/00

CPC分类号： G07C9/00158 ,  G06F21/32 ,  H04L9/3228 ,  H04L9/3231

摘要： In a biometric authentication system, a delivery server includes a parameter conversion unit which generates, by converting the parameter, a parameter for delivery, a template conversion unit which generates, by converting the template, a template for delivery, and a delivery unit which delivers the template for delivery and the parameter for delivery to one of the client terminal and an authentication device; the authentication device includes a sensor which obtains biometric information on a registered user, a feature quantity obtaining unit which obtains a feature quantity from the biometric information, and a feature quantity conversion unit which generates, by converting the feature quantity using the parameter for delivery, a converted feature quantity; and the client terminal includes a match determination unit which determines, by comparing the converted feature quantity with the template for delivery, whether or not the converted feature quantity and the template for delivery match.

摘要翻译： 在生物体认证系统中，传送服务器包括参数转换单元，该参数转换单元通过转换参数来生成用于传送的参数，模板转换单元，其通过转换模板来生成用于传递的模板，以及递送单元 用于传送的模板和用于传送到客户端终端和认证设备之一的参数; 所述认证装置包括获取对登录用户的生物体信息的传感器，从所述生物体信息获取特征量的特征量获取单元，以及特征量变换单元，其通过使用所述传送用参数转换所述特征量， 转换的特征量; 并且客户终端包括匹配确定单元，其通过将转换的特征量与用于传递的模板进行比较来确定转换的特征量和用于传送的模板是否匹配。